Antimicrobial resistance: a class effect?
|
|
- Denis Parsons
- 5 years ago
- Views:
Transcription
1 Journal of Antimicrobial Chemotherapy (2002) 50, Suppl. S2, 7 12 DOI: /jac/dkf508 Antimicrobial resistance: a class effect? J. Prieto*, A. Calvo and M. L. Gómez-Lus Microbiology I Department, School of Medicine, Universidad Complutense, Avda Complutense s/n, Madrid, Spain Antibiotic use has led to increased resistance to certain group markers: penicillin, erythromycin and ciprofloxacin for β-lactams, macrolides and quinolones, respectively. The influence of resistance to markers in decreasing susceptibility to the drugs included (on the basis of chemical structure) in the corresponding antibiotic group can be defined as resistance class effect. In the case of macrolides, this effect is dependent on the prevalent resistant phenotype among the isolates of the target bacteria: the class effect exists completely if the mechanism of resistance is constitutive MLS B (all macrolides are affected by resistance to erythromycin), and only partially if the mechanism is the efflux M phenotype (all but 16-membered macrolides are affected). In Spain, the first case is exemplified by Streptococcus pneumoniae and the second by Streptococcus pyogenes. For β-lactams and quinolones, resistance to the group markers results in large decreases in the antimicrobial activity of the less potent members of the group, penicillin being a better driver of resistance for oral cephalosporins than for aminopenicillins, and ciprofloxacin being a better driver for older rather than for the newer quinolones, which have enhanced anti-pneumococcal activity. Empirical prescription guidelines based on the pharmacoepidemiology of resistance, recommending the use of potent drugs that are less influenced by resistance to the marker, may help to counter the spread of resistance in the community. Introduction Resistance is associated with the use of antimicrobial agents. 1,2 This is clearly evident in community-acquired respiratory tract infections (RTIs), where the development and dissemination of resistance have been related to consumption. 3 5 Since 90% of antibiotic use is in the community and 80% of this for the treatment of RTIs, 6 antibiotic treatment of community-acquired RTIs may be the leading cause of the resistance problem. Two of the most prevalent bacterial species isolated from RTIs present problems with respect to susceptibility: Streptococcus pneumoniae in relation to β-lactams, macrolides and quinolones; and Streptococcus pyogenes in relation to macrolides, to an increasing extent. This widely recognized problem 7 has posed difficulties, particularly with respect to the treatment of RTI, because of the need to select appropriate treatment empirically. Infecting organisms, if isolated, are categorized as susceptible or resistant up to several days after treatment has been initiated. So, despite the fact that prudent antimicrobial prescribing in the community may help to prevent the relentless increase in resistance, 7 the term prudent has to be used generally (from a population perspective) without the knowledge of the likely effectiveness of the antibiotic being used for a specific patient. In other words, empirical treatment is based mainly on epidemiological data. Prescribing in primary care is influenced by several factors influencing appropriate antibiotic use by general practitioners. 7 Guidelines based on treatment costs and clinical outcomes have probably had little effect on the emergence 8 and spread of resistance. Therefore, alternative guidelines could be based on the bacterial (resistance) and drug (antimicrobial effects against bacteria) factors that might counter resistance, since there is increasing evidence confirming that maximal reduction of the bacterial load (and in the end, bacterial eradication) should be the primary goal of antibiotic therapy. 8,9 Markers of resistance The antibiotics most frequently prescribed in communityacquired RTI are from three major groups: β-lactams, macrolides and quinolones. Among β-lactams, aminopenicillins are used more than oral cephalosporins 4,5 and recently long halflife macrolides have been used more frequently in Spain than those given more than twice a day. 3 5 The use of quinolones for the treatment of RTI is also increasing. 10,11... *Corresponding author. jprieto@med.ucm.es The British Society for Antimicrobial Chemotherapy
2 J. Prieto et al. Most studies of resistance use the term resistance with respect to the susceptibility to penicillin, erythromycin and ciprofloxacin. For this reason, it can be inferred that resistance to these antibiotics is generally considered as a marker for resistance to β-lactams, macrolides and quinolones, respectively. Because those antibiotics with lower intrinsic activity (oral cephalosporins versus aminopenicillins) or that reach lower concentrations in blood or tissue (longer selective windows of resistance) 12,13 have a greater responsibility in causing resistance to antibiotic markers (their consumption has greater influence on the emergence, maintenance and spread of resistance in the general population), 3 5 then the critical question is whether a decrease in susceptibility to the antibiotic marker implies a decrease in the antimicrobial activity of the drugs included in the corresponding group. The resistance class effect can be defined as an affirmative answer to this question, in that a decrease in susceptibility to the antibiotic marker affects equally all compounds in the antibiotic class. This concept is needed because, in terms of resistance, it does not seem logical to group drugs with different microbiological, pharmacokinetic and pharmacodynamic properties (and thus with different capabilities of resistance selection) only on the basis of their similar chemical structure. 14 Moreover, the problem should be analysed by combining bacterial species with specific antibiotics, since the class effect may occur for some antibiotic groups but not for others, or within an antibiotic group for some bacterial species but not for others. Resistance to β-lactams: a class effect? Does an increase in penicillin MIC affect to a similar extent the activity of all β-lactams against S. pneumoniae and S. pyogenes? Following NCCLS guidelines, 15 penicillin is a good marker of resistance with respect to the susceptibility of S. pyogenes to β-lactams: an isolate susceptible to penicillin should be considered susceptible to all β-lactams. In this case, the use of β-lactams has not resulted in the appearance of in vitro resistance in S. pyogenes, 16 probably due to the absence of selectable variants carrying mechanisms of resistance to β-lactams in this bacterial species. 3 One hundred per cent of S. pyogenes isolates remain susceptible to penicillin and thus to all β-lactams. With respect to S. pneumoniae, the latest surveillance carried out in Spain (1684 isolates) showed a prevalence of highly resistant strains of 5% for aminopenicillins, 7% for cefotaxime, 22% for penicillin, 31% for cefuroxime and 42% for cefaclor. 17 While resistance to aminopenicillins (intermediate or high) is only clustered in the 22% of strains showing high resistance to penicillin (resistance among strains susceptible or intermediately resistant to penicillin being practically absent), high rates (>35%) of high-level resistance were obtained for oral cephalosporins among penicillinintermediate and -resistant strains. Resistance to cefotaxime (mostly intermediate) was clustered at lower rates in strains showing intermediate resistance to penicillin but at high rates amongst the highly penicillin-resistant strains, although breakpoints to third generation cephalosporins (which have proved useful for penicillin-resistant strains in communityacquired pneumonia) 18 may be too low for the prediction of efficacy in RTI. 17 Differences in activity between β-lactams have also been found in other surveillance studies In terms of the differential activity of β-lactams for S. pneumoniae, several groups are proposed. The first group would include those compounds with higher activity than penicillin, such as amoxicillin, co-amoxiclav and cefotaxime. The second group would include those antibiotics with slightly higher activity than penicillin, such as cefuroxime. The third group would be those antibiotics with lower activity than penicillin, such as cefixime or cefaclor. Therefore, in relation to in vitro bacteriostatic activity, penicillin resistance is a good marker of resistance to oral cephalosporins, but not to aminopenicillins. This has an analogy in studies investigating the influence of the increase in penicillin MIC on the bactericidal activity of several β-lactams, where aminopenicillins were affected to a lesser extent than oral cephalosporins in in vitro experiments and to a similar extent to parenteral cephalosporins in ex vivo experiments. 25 Again, in terms of in vivo efficacy, the effect that the increase in the penicillin MIC had on the efficacy of β-lactams was not uniform, being lower for amoxicillin versus oral cephalosporins in sepsis 26,27 and otitis 28,29 animal models. Higher in vivo bactericidal activity of amoxicillin was demonstrated in an animal sepsis model where amoxicillin showed greater clearance of bacteraemia (and thus, an increase in survival rates) than cefotaxime against a serotype 6 penicillin-resistant strain (with MICs of 2 and 4 mg/l cefotaxime and amoxicillin, respectively). 30 Limited documentation on therapeutic failures in patients with adequate doses of β-lactams in pneumococcal RTI, 31 and the in vivo experience in animal models suggest that penicillin resistance is not a good marker of β-lactam resistance when prediction of therapeutic efficacy is needed. Macrolides: a class effect? Does the increase in erythromycin MIC affect to a similar extent the activity of all macrolides against S. pneumoniae and S. pyogenes? In this case, the response depends on the mechanism of resistance exhibited by the target bacteria. Two main mechanisms of resistance are exhibited by the two most prevalent Grampositive cocci in community-acquired RTI: S. pneumoniae and S. pyogenes. One mechanism depends on target modification and is the constitutive MLS B phenotype, which 8
3 Antimicrobial resistance: a class effect? determines high-level and cross-resistance to 14-, 15- and 16-membered macrolides, lincosamides, clindamycin and streptogramin B. 32 The other mechanism depends on the efflux of drugs and is the M phenotype, which confers lowlevel resistance to 14- and 15-membered macrolides, while not affecting 16-membered macrolides (espiramycin and josamycin), lincosamides, streptogramins or ketolides, which remain fully active. 32,33 Therefore, the problem should be analysed by geographical area, since erythromycin is a good marker of resistance to macrolides in areas where the prevalent mechanism of resistance is the constitutive MLS B phenotype, but not in areas where the prevalent mechanism of resistance is the M efflux phenotype, since strains carrying this type of resistance mechanism are susceptible to 16-membered macrolides. In Spain, the prevalence of resistance to erythromycin is 35% in S. pneumoniae and 20% in S. pyogenes. 17 While 90% of S. pneumoniae resistant to erythromycin exhibit the constitutive MLS B resistance phenotype, 90% of S. pyogenes resistant to erythromycin exhibit the M efflux phenotype. 17 Since both mechanisms of erythromycin resistance imply resistance to 14- and 15-membered macrolides, erythromycin is a good marker of resistance to clarithromycin and azithromycin in both species. Thus, when 16-membered macrolides are also considered, erythromycin is only a good marker of resistance for the whole antibiotic group in S. pneumoniae but not in S. pyogenes. The local prevalence of mechanisms of resistance is critical for macrolide prescribing since the very high MIC 90 ( 64 mg/l) 17 obtained with the constitutive MLS B mechanism demands strategies using larger doses that might exceed those concentrations. In any case, the MIC 90 (8 mg/l) 17 of erythromycin, clarithromycin and azithromycin for strains with the efflux M mechanism cannot be exceeded by standard oral doses of these antibiotics. The level of resistance is reflected therapeutically, and clinical failures have been described 34,35 with macrolides in bacteraemic respiratory infections caused by S. pneumoniae with the constitutive MLS B phenotype prevalent in Spain. Thus, in this country, erythromycin resistance is a marker of the therapeutic outcome of clarithromycin and azithromycin treatments for infections caused by S. pneumoniae. There appears little doubt that macrolide resistance correlates directly with clinical failure and that guidelines should exclude macrolides in areas of rising resistance prevalence. 8 Quinolones: a class effect? Does the increase in ciprofloxacin MIC affect to a similar extent the activity of all quinolones against S. pneumoniae? Resistance rates to quinolones in respiratory pathogens are relatively low, 10,36 but the current wide use of quinolones could cause future problems of resistance. The new fluoroquinolones show an activity greater than that of ciprofloxacin. 37,38 The use of quinolones has been related to ciprofloxacin resistance, 11 but logically it has to be attributed to older quinolones, since the new ones, with enhanced antipneumococcal activity, were not marketed. In Spain, the prevalence of ciprofloxacin resistance is 6% for high-level resistance (MIC 4 mg/l) and 22% for an MIC 2 mg/l. 10 While new quinolones exhibit high activity against S. pneumoniae 39 susceptible to ciprofloxacin (MIC 2 mg/l), an increase in the MICs of all quinolones occurs for ciprofloxacin-resistant strains (MIC 4 mg/l). Nevertheless, this increase is not equal for all drugs, being lower for gemifloxacin than for trovafloxacin, 40 clinafloxacin and moxifloxacin (MICs < 0.25 mg/l of all of them for ciprofloxacin-susceptible strains compared with MIC 90 of 0.5, 1, 4 and 8 mg/l of gemifloxacin, clinafloxacin, moxifloxacin and trovafloxacin, respectively, for strains with ciprofloxacin MIC 8 mg/l). 41 In terms of percentages of resistance to the new quinolones, the increase in ciprofloxacin MIC 41 did not affect gemifloxacin (since the MIC 90 remained constantly equal to or lower than the proposed 0.5 mg/l breakpoint 42 ) or clinafloxacin (MIC 90 remained <1 mg/l), while it affected moxifloxacin and trovafloxacin [MIC 90 higher than the NCCLS susceptibility breakpoints ( 1 mg/l) 15 ]. As expected, an increase in the MIC of ciprofloxacin influenced to a higher degree resistance to the older quinolones such as ofloxacin, grepafloxacin and sparfloxacin. 41 In a different study, gemifloxacin was also the quinolone least affected by both a decrease in in vitro susceptibility to ciprofloxacin and the presence of human serum. 43 These effects on in vitro bacteriostatic activity were also found when in vitro bactericidal activity was assessed in the presence of human serum in a study with concentrations similar to peak and trough serum concentrations in humans after standard doses of ciprofloxacin, gemifloxacin and trovafloxacin. 44 At peak concentrations, gemifloxacin decreased by 99.9% the initial inocula of four strains exhibiting ciprofloxacin MICs ranging from 0.5 to 16 mg/l, and showed significant bactericidal activity at trough concentrations, thus theoretically preventing regrowth over the dosing interval. 44 Ciprofloxacin and trovafloxacin did not obtain a reduction for any of the four strains tested. 44 This lesser effect on gemifloxacin was also corroborated in a Phase I study demonstrating that the ex vivo bactericidal activity of gemifloxacin was less influenced than that of trovafloxacin by the decrease in ciprofloxacin MIC exhibited by the strains tested. 45 In animal models, the gemifloxacin AUC:MIC ratios producing a 2 log kill over 24 h (a parameter related to survival) were similar against ciprofloxacin-susceptible and -resistant strains, 46 using an AUC similar to that obtained in humans. In the clinical setting, therapeutic failures have been described with older quinolones, 47 including levofloxacin, 48 9
4 J. Prieto et al. but the intrinsic activity of new fluoroquinolones may counter the risk derived from the increased prevalence of ciprofloxacin resistance. 14 In conclusion, the class effect in the quinolone group is similar to that of β-lactams: the group marker of resistance is a better determinant of resistance for the compounds with lower intrinsic activity than for the more potent ones, i.e. ciprofloxacin is a good predictor of resistance for older quinolones but not for the very new ones. Conclusions Resistance is a global problem among the most prevalent respiratory isolates. In areas with a high prevalence of resistance to macrolides in S. pyogenes, there is a high prevalence of resistance to macrolides in S. pneumoniae. 17 Areas with a high prevalence of resistance to macrolides in S. pneumoniae are also associated with resistance to penicillin. 17 In addition, ciprofloxacin resistance is clustered in strains with erythromycin resistance and with penicillin non-susceptibility. 10,17 From this situation, it can be concluded that resistance is a global problem with a geographical basis in RTIs. Because of this, empirical treatments aimed at decreasing the bacterial load in infected patients to avoid the spread of clonal resistant strains should be based on local data on prevalence of resistance and of resistance phenotypes. Due to the clustering of resistance to different markers in the same clones, success in the fight against penicillin resistance implies a decrease in erythromycin resistance and ciprofloxacin resistance in S. pneumoniae. In Spain, macrolides are not able to overcome the overall problem of resistance since resistance to erythromycin exerts a class effect over all macrolides in S. pneumoniae and a partial class effect (only to 14- and 15-membered macrolides) in S. pyogenes due to the prevalence of the respective resistance phenotypes. For this reason, the most active oral β-lactams (aminopenicillins) are, among the currently available antibiotics, a good option for empirical treatment of infants and adults in the community, and could also counter the spread of penicillin resistance. New quinolones are also an option provided they are not influenced in the future by the increase in resistance to the group marker. In conclusion, bacterial and antibiotic factors should be considered when selecting an empirical treatment for community-acquired RTI by using the most suitable antibiotic class (as defined by epidemiological data) and within it, the most potent antibiotic that is least affected by a decrease in susceptibility to the group marker. Acknowledgements We would like to thank M. J. Giménez and L. Aguilar for their critical review of the manuscript. References 1. Magee, J. T., Pritchard, E. L., Fitzgerald, K. A., Dunstan, F. D. & Howard, A. J. (1999). Antibiotic prescribing and antibiotic resistance in community practice: retrospective study British Medical Journal 319, Arason, V. A., Kristinsson, K. G., Sigurdsson, J. A., Stefansdottir, G., Molstad, S. & Gudmundsson, S. (1996). Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study. British Medical Journal 313, Granizo, J. J., Aguilar, L., Casal, J., Dal-Ré, R. & Baquero, F. (2000). Streptococcus pyogenes resistance to erythromycin in relation to macrolide consumption in Spain ( ). Journal of Antimicrobial Chemotherapy 46, Granizo, J. J., Aguilar, L., Casal, J., García-Rey, C., Dal-Ré, R. & Baquero, F. (2000). Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and β-lactam consumption in Spain ( ). Journal of Antimicrobial Chemotherapy 46, García-Rey, C., Aguilar, L., Baquero, F., Casal, J. & Dal-Ré, R. (2002). Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae. Journal of Clinical Microbiology 40, Huovinen, P. & Cars, O. (1998). Control of antimicrobial resistance: time for action. British Medical Journal 317, McNulty, C. A. M. (2001). Optimising antibiotic prescribing in primary care. International Journal of Antimicrobial Agents 18, Ball, P., Baquero, F., Cars, O., File, T., Garau, J., Klugman, K. et al. (2002). Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. Journal of Antimicrobial Chemotherapy 49, Dagan, R., Klugman, K. P., Craig, W. A. & Baquero, F. (2001). Evidence to support the rationale that bacterial eradication in respiratory tract infection provides guidance for antimicrobial therapy. Journal of Antimicrobial Chemotherapy 47, García-Rey, C., Aguilar, L., Baquero, F. & The Spanish Surveillance Group for Respiratory Pathogens. (2000). Influences of different factors on prevalence of ciprofloxacin resistance in Streptococcus pneumoniae in Spain. Antimicrobial Agents and Chemotherapy 44, Chen, D. K., McGeer, A., De Azavedo, J. C. & Low, D. E. (1999). Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. New England Journal of Medicine 341, Baquero, F. (1999). Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption? Journal of Chemotherapy 11, Suppl. 1, Drusano, G. L. & Craig, W. A. (1997). Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. Journal of Chemotherapy 9, Suppl. 3, Aguilar, L., García-Rey, C. & Giménez, M. J. (2001). Presión antibiótica, desarrollo de resistencias en Streptococcus pneumo- 10
5 Antimicrobial resistance: a class effect? niae y fracaso clínico: un círculo no tan vicioso para algunos antibióticos. Revista Espanola de Quimioterapia 14, National Committee for Clinical Laboratory Standards. (2000). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically Fifth Edition: Approved Standard M7-A5. NCCLS, Wayne, PA, USA. 16. Gerber, M. A. (1995). Antibiotic resistance in Group A streptococci. Pediatric Clinics of North America 42, Pérez-Trallero, E., Fernández-Mazarrasa, C., García-Rey, C., Bouza, E., Aguilar, L., García-de-Lomas, J. et al. (2001). Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: Results of a 1-year ( ) multicenter surveillance study in Spain. Antimicrobial Agents and Chemotherapy 45, Roson, B., Carratalá, J., Tubau, F., Dorca, J., Liñares, J., Pallarés, R. et al. (2001). Usefulness of β-lactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin clavulanate and ceftriaxone. Microbial Drug Resistance 7, Sahm, D. F., Jones, M. E., Hickey, M. L., Diakun, D. R., Mani, S. V. & Thornsberry, C. (2000). Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, Journal of Antimicrobial Chemotherapy 45, Felmingham, D., Grüneberg, R. N. & the Alexander Project Group. (2000). The Alexander Project : latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 45, Oteo, J., Alós, J. I. & Gómez-Garcés, J. L. (2001). Antimicrobial resistance of Streptococcus pneumoniae isolates in 1999 and 2000 in Madrid, Spain: a multicentre surveillance study. Journal of Antimicrobial Chemotherapy 47, Fenoll, A., Casal, J., Giménez, M. J., Jado, I. & Aguilar, L. (2000). Short-term bactericidal activity of amoxicillin and cefotaxime against penicillin susceptible and resistant pneumococcal strains: An in vitro pharmacodynamic simulation. Journal of Chemotherapy 12, Prieto, J., Giménez, M. J., Balcabao, I. P., Gómez-Lus, M. L. & Aguilar, L. (1999). Does the degree of penicillin susceptibility of Streptococcus pneumoniae affect the bactericidal activity of coamoxiclav versus oral cephalosporins at physiological concentrations? An in vitro pharmacodynamic simulation. Journal of Chemotherapy 11, Balcabao, I. P., Aguilar, L., Martín, M., García, Y., Dal-Ré, R. & Prieto, J. (1996). Activities against Streptococcus pneumoniae of amoxicillin and cefotaxime at physiological concentrations: in vitro pharmacodynamic simulation. Antimicrobial Agents and Chemotherapy 40, Aguilar, L., Rosendo, J., Balcabao, I. P., Martin, M., Gimenez, M. J., Frias, J. et al. (1997). Pharmacodynamic effects of amoxicillin versus cefotaxime against penicillin-susceptible and penicillinresistant pneumococcal strains: a phase I study. Antimicrobial Agents and Chemotherapy 41, Soriano, F., Ponte, C., Nieto, E. & Parra, A. (1996). Correlation of in-vitro activity and pharmacokinetic parameters with in-vivo effect of amoxycillin, co-amoxiclav and cefotaxime in a murine model of pneumococcal pneumonia. Journal of Antimicrobial Chemotherapy 38, Pérez-Trallero, E., Alkorta, M., Giménez, M. J., Vicente, D. & Aguilar, L. (2001). Prediction of in-vivo efficacy by in-vitro early bactericidal activity, with oral β-lactams, in a dose-ranging immunocompetent mouse sepsis model, using strains of Streptococcus pneumoniae with decreasing susceptibilities to penicillin. Journal of Chemotherapy 13, Cenjor, C., Ponte, C., Parra, A., Nieto, V., García-Calvo, G., Giménez, M. J. et al. (1998). In vivo efficacy of amoxicillin and cefuroxime against penicillin-resistant Streptococcus pneumoniae in a gerbil model of acute otitis media. Antimicrobial Agents and Chemotherapy 42, Soriano, F., Parra, A., Cenjor, C., Nieto, E., García-Calvo, G., Giménez, M. J. et al. (2000). Role of Streptococcus pneumoniae and Haemophilus influenzae in the development of acute otitis media and otitis media with effusion in a gerbil model. Journal of Infectious Diseases 181, Yuste, J., Jado, I., Fenoll, A., Aguilar, L., Giménez, M. J. & Casal, J. (2002). β-lactam modification of the bacteraemic profile and its relationship with mortality in a pneumococcal mouse sepsis model. Journal of Antimicrobial Chemotherapy 49, Soriano, F. (1999). Lectura farmacodinámica de la sensibilidad antibiótica a Streptococcus pneumoniae. Medicina Clínica 113, Mlynarczyk, G., Mlynarczyk, A. & Jeljaszewicz, J. (2001). Epidemiological aspects of antibiotic resistance in respiratory pathogens. International Journal of Antimicrobial Agents 18, Alós, J. I., Aracil, B., Oteo, J., Torres, C., Gómez-Garcés, J. L. & the Spanish Group for the Study of Infection in the Primary Health Care Setting. (2000). High prevalence of erythromycin-resistant, clindamycin/miocamycin-susceptible (M phenotype) Streptococcus pyogenes: results of a Spanish multicentre study in Journal of Antimicrobial Chemotherapy 45, Kelly, M. A., Weber, D. J., Gilligan, P. & Cohen, M. S. (2000). Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clinical Infectious Diseases 31, Garau, J., Lonks, J. R., Gómez, L., Xercavins, M. & Medeiros, A. (2000). Failure of macrolide therapy in patients with bacteremia due to macrolide resistant Streptococcus pneumoniae. In Program and Abstracts of the Fifth International Conference on Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones, Seville, Abstract Buxbaum, A., Straschil, U., Moser, C., Graninger, W., Georgopoulos, A. & the Austrian Bacterial Surveillance Network. (1999). Comparative susceptibility to penicillin and quinolones of 1385 Streptococcus pneumoniae isolates. Journal of Antimicrobial Chemotherapy 43, Loza, E., Morosoni, M. I., Negri, M. C., Almaraz, F., Cantón, R., Baquero, F. et al. (2000). Estudio multicéntrico nacional de la actividad in vitro de moxifloxacino frente a patógenos respiratorios. Revista Espanola de Quimioterapia 13, Rittenhouse, S., McCloskey, L., Broskey, J., Niconovich, N., Jakielaszek, C., Poupard, J. et al. (2000). In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens. Journal of Antimicrobial Chemotherapy 45, Suppl. 1,
6 J. Prieto et al. 39. García-Garrote, F., Cercenado, E., Martín-Pedroviejo, J. & Bouza, E. (1999). Comparative in vitro activity of gemifloxacin (SB ) with other fluoroquinolones against Streptococcus pneumoniae and Haemophilus influenzae. In Program and Abstracts of the Thirty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, Abstract 2296, p American Society for Microbiology, Washington, DC, USA. 40. Fuentes, F., Giménez, M. J., Marco, F., Alou, L., Aguilar, L. & Prieto, J. (2000). In vitro susceptibility to gemifloxacin and trovafloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin. European Journal of Clinical Microbiology and Infectious Diseases 19, Pérez-Trallero, E., Larruskain, J., Marimon, J. M., Ayestaran, I. & García-Arenzana, J. M. (2001). In vitro activities of 10 fluoroquinolones against clinical isolates of Streptococcus pneumoniae during 1999 and 2000 in Gipuzkoa, Spain. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, Abstract E-727, p American Society for Microbiology, Washington, DC, USA. 42. Wise, R. & Andrews, J. M. (1999). The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone. Journal of Antimicrobial Chemotherapy 44, Balcabao, I. P., Alou, L., Aguilar, L., Gomez-Lus, M. L., Giménez, M. J. & Prieto, J. (2001). Influence of the decrease in ciprofloxacin susceptibility and the presence of human serum on the in vitro susceptibility of Streptococcus pneumoniae to five new quinolones. Journal of Antimicrobial Chemotherapy 48, Joyanes, P., Pascual, A., Giménez, M. J., García, I., Aguilar, L. & Perea, E. (2001). Differences between two new quinolones (gemifloxacin and trovafloxacin) and ciprofloxacin in their concentrationdependent killing of Streptococcus pneumoniae. Chemotherapy 47, Prieto, J., Aguilar, L., Fuentes, F., Giménez, M. J., Alou, L., Dal-Ré, R. et al. (2001). Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. International Journal of Antimicrobial Agents 18, Woodnutt, G. (2000). Pharmacodynamics to combat resistance. Journal of Antimicrobial Chemotherapy 46, Topic T1, Pérez-Trallero, E., García-Arenzana, J. M., Jiménez, J. A. & Peris, A. (1990). Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin. European Journal of Clinical Microbiology and Infectious Diseases 9, Empey, P. E., Jennings, H. R., Thornton, A. C., Rapp, R. P. & Evans, M. E. (2001). Levofloxacin failure in a patient with pneumococcal pneumonia. Annals of Pharmacotherapy 35,
ORIGINAL ARTICLE. Focus Technologies, Inc., 1 Hilversum, The Netherlands, 2 Herndon, Virginia and 3 Franklin, Tennessee, USA
ORIGINAL ARTICLE In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000 2001 M. E. Jones 1, R. S. Blosser-Middleton
More informationand Health Sciences, Wayne State University and Detroit Receiving Hospital, Detroit, MI, USA
Journal of Antimicrobial Chemotherapy (2004) 54, Suppl. S1, i7 i15 DOI: 10.1093/jac/dkh313 JAC Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae
More informationparameters were enhanced to develop new antimicrobial formulations CONSIDERATIONS IN ANTIMICROBIAL SELECTION Using animal models and human data, PK an
Overview of Newer Antimicrobial Formulations for Overcoming Pneumococcal Resistance William A Craig, MD The pharmacokinetic (PK) and pharmacodynamic (PD) profile of an antimicrobial agent provides important
More informationDoes the Dose Matter?
SUPPLEMENT ARTICLE Does the Dose Matter? William A. Craig Department of Medicine, University of Wisconsin, Madison, Wisconsin Pharmacokinetic/pharmacodynamic (PK/PD) parameters, such as the ratio of peak
More informationAnnual Report: Table 1. Antimicrobial Susceptibility Results for 2,488 Isolates of S. pneumoniae Collected Nationally, 2005 MIC (µg/ml)
Streptococcus pneumoniae Annual Report: 5 In 5, a total of, isolates of pneumococci were collected from 59 clinical microbiology laboratories across Canada. Of these, 733 (9.5%) were isolated from blood
More informationAntibiotic Kinetic and Dynamic Attributes for Community-Acquired Respiratory Tract Infections
...PRESENTATIONS... Antibiotic Kinetic and Dynamic Attributes for Community-Acquired Respiratory Tract Infections David P. Nicolau, PharmD Presentation Summary Factors, including the age of the treatment
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationA review of antibiotic resistance patterns of Streptococcus pneumoniae in Europe
Journal of Antimicrobial Chemotherapy (1991) 28, Suppl. C, 31-38 A review of antibiotic resistance patterns of Streptococcus pneumoniae in Europe F. Baqoero*, J. Martfnez-Beltran and E. Loza Servicio de
More informationNational Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014
More informationBacterial Resistance of Respiratory Pathogens. John C. Rotschafer, Pharm.D. University of Minnesota
Bacterial Resistance of Respiratory Pathogens John C. Rotschafer, Pharm.D. University of Minnesota Antibiotic Misuse ~150 million courses of antibiotic prescribed by office based prescribers Estimated
More informationMarc Decramer 3. Respiratory Division, University Hospitals Leuven, Leuven, Belgium
AAC Accepts, published online ahead of print on April 0 Antimicrob. Agents Chemother. doi:./aac.0001- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationResistance Among Streptococcus pneumoniae: Patterns, Mechanisms, Interpreting the Breakpoints
...PRESENTATIONS... Resistance Among Streptococcus pneumoniae: Patterns, Mechanisms, Interpreting the Breakpoints Angela B. Brueggemann, MS; and Gary V. Doern, PhD Presentation Summary Streptococcus pneumoniae
More informationBrief reports. Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae
Journal of Antimicrobial Chemotherapy (1997) 40, 105 108 Brief reports JAC Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae Andreas Pikis a *, Jacob A. Donkersloot
More informationAnimal models and PK/PD. Examples with selected antibiotics
Animal models and PK/PD PD Examples with selected antibiotics Examples of animal models Amoxicillin Amoxicillin-clavulanate Macrolides Quinolones Andes D, Craig WA. AAC 199, :375 Amoxicillin in mouse thigh
More informationKeywords: amoxicillin/clavulanate, respiratory tract infection, antimicrobial resistance, pharmacokinetics/pharmacodynamics, appropriate prescribing
Journal of Antimicrobial Chemotherapy (2004) 53, Suppl. S1, i3 i20 DOI: 10.1093/jac/dkh050 Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review
More informationRESISTANCE, USE, INTERVENTIONS. Hugh Webb
RESISTANCE, USE, INTERVENTIONS Hugh Webb EU Initiatives: EARSS and ESAC. Antimicrobial Use and Resistance The Relationship. Bias and confounding in published studies. Mathematical modelling of resistance
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062
More informationChoosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections
...CLINICIAN INTERVIEW... Choosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections An interview with Robert C. Owens, Jr., PharmD, Clinical Pharmacy
More informationORIGINAL ARTICLE. influenzae and Moraxella catarrhalis to antimicrobial agents used to treat respiratory tract infections.
ORIGINAL ARTICLE Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis collected from five centers in Brazil, 1997 98 I. A. Critchley 1, C. Thornsberry
More informationThe World Health Organization has referred to. Antibiotic Resistance: The Iowa Experience DRUG UTILIZATION. Nancy Bell, RPh
DRUG UTILIZATION Antibiotic Resistance: The Iowa Experience Nancy Bell, RPh Background: In the past 10 years, the number of strains of Streptococcus pneumoniae and other common respiratory pathogens that
More informationAntibiotic consumption and resistance selection in Streptococcus pneumoniae
Journal of Antimicrobial Chemotherapy (2002) 50, Suppl. S2, 27 37 DOI: 10.1093/jac/dkf504 Antibiotic consumption and resistance selection in Streptococcus pneumoniae Fernando Baquero 1 *, Gregorio Baquero-Artigao
More informationESCMID Online Lecture Library. by author
Treatment of community-acquired meningitis including difficult to treat organisms like penicillinresistant pneumococci and guidelines (ID perspective) Stefan Zimmerli, MD Institute for Infectious Diseases
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationORIGINAL ARTICLE /j x. Western Reserve University, Cleveland, OH, USA and 3 Wockhardt Research Centre, Aurangabad, India
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.01017.x Activity of the new quinolone WCK 771 against pneumococci P. C. Appelbaum 1, G. A. Pankuch 1, B. Bozdogan 1, G. Lin 1, M. R. Jacobs 2, M. V. Patel 3, S.
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationBreakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral β-lactams
Journal of Antimicrobial Chemotherapy (2003) 51, 691 696 DOI: 10.1093/jac/dkg116 Advance Access publication 28 January 2003 Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin
More informationAlasdair P. MacGowan*, Mandy Wootton and H. Alan Holt
Journal of Antimicrobial Chemotherapy (1999) 43, 345 349 JAC The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial
More informationJ. M. Blondeau*, M. Suter, S. Borsos and the Canadian Antimicrobial Study Group
Journal of Antimicrobial Chemotherapy (1999) 43, Suppl. A, 25 30 JAC Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella
More informationClinical efficacy of cefpodoxime in respiratory tract infection
Journal of Antimicrobial Chemotherapy (2002) 50, Topic T1, 23 27 DOI: 10.1093/jac/dkf805 Clinical efficacy of cefpodoxime in respiratory tract infection Robert Cohen* Department of Microbiology, Intercommunal
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More informationCHSPSC, LLC Antimicrobial Stewardship Education Series
CHSPSC, LLC Antimicrobial Stewardship Education Series March 8, 2017 Pharmacokinetics/Pharmacodynamics of Antibiotics: Refresher Part 1 Featured Speaker: Larry Danziger, Pharm.D. Professor of Pharmacy
More informationEinheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?
Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how? Andrea Duppenthaler andrea.duppenthaler@insel.ch Limping patient local pain swelling tenderness warmth fever acute Osteomyelitis
More informationTreatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani
Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:
More informationReceived 27 August 2002; returned 26 November 2002; revised 8 January 2003; accepted 11 January 2003
Journal of Antimicrobial Chemotherapy (2003) 51, 905 911 DOI: 10.1093/jac/dkg152 Advance Access publication 13 March 2003 AUC 0 t /MIC is a continuous index of fluoroquinolone exposure and predictive of
More informationDETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY*
44 DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* AUTHOR: Cecilia C. Maramba-Lazarte, MD, MScID University of the Philippines College of Medicine-Philippine
More information...CONTINUING MEDICAL EDUCATION...
...CONTINUING MEDICAL EDUCATION...... Drug Resistance and the Treatment of Upper Respiratory Infections GOAL To provide comprehensive and up-to-date information concerning drug resistance and the implications
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationCommunity Acquired Pneumonia: An Update on Guidelines
Community Acquired Pneumonia: An Update on Guidelines Claudia Summa, BScPhm Pharmacy Resident September 12, 2006 Objectives To give a brief description of the pathophysiology of community acquired pneumonia
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationSUPPLEMENT ARTICLE. among clinical isolates of S. pneumoniae in the United
SUPPLEMENT ARTICLE Regional Trends in Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: Results from
More informationOver 40 Posters/Abstracts in Support of TREK Presented at the 2004 ECCMID
Over 40 Posters/Abstracts in Support of TREK Presented at the ECCMID This was our best ECCMID ever for TREK presentations! The following posters and abstracts were in support of TREK products! Sensititre
More informationAntibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice?
Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice? With the support of Wallonie-Bruxelles-International 1-1 In vitro evaluation of antibiotics : the antibiogram
More informationACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective
ACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective Antwerpen 8 november 2002 Yvan Valcke MD PhD AZ Maria Middelares Sint-Niklaas ACUTE EXACERBATIONS of COPD (AE-COPD) Treatment of AECB Role
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationJAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro
Journal of Antimicrobial Chemotherapy (1997) 39, 713 717 JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro Ian Morrissey* Department of Biosciences, Division of Biochemistry
More informationPK/PD to fight resistance
PK/PD to fight resistance Eradicate Abnormal bacteria Mutations Efflux pumps Mutation-Preventing Concentration Breakpoint values for T > MIC and in practice With the support of Wallonie-Bruxelles-International
More informationThe evolutionary epidemiology of antibiotic resistance evolution
The evolutionary epidemiology of antibiotic resistance evolution François Blanquart, CNRS Stochastic Models for the Inference of Life Evolution CIRB Collège de France Quantitative Evolutionary Microbiology
More informationL. Alou 1, M. J. Giménez 1, D. Sevillano 1, L. Aguilar 1 *, N. González 1, O. Echeverría 1, M. Torrico 1, P. Coronel 2 and J.
Journal of Antimicrobial Chemotherapy (2007) 59, 652 657 doi:10.1093/jac/dkm015 Advance Access publication 6 March 2007 Are b-lactam breakpoints adequate to define non-susceptibility for all Haemophilus
More informationAntibiotics & treatment of Acute Bcterial Sinusitis. Walid Reda Product Manager. Do your antimicrobial options meet your needs?
Antibiotics & treatment of Acute Bcterial Sinusitis Walid Reda Product Manager Do your antimicrobial options meet your needs? Antimicrobial Effects: What s involved? Effect in Humans: Serum concentration
More informationReceived 29 September 2005; returned 6 December 2005; revised 25 January 2006; accepted 30 January 2006
Journal of Antimicrobial Chemotherapy (26) 57, 714 719 doi:1.193/jac/dkl41 Advance Access publication 21 February 26 Urine bactericidal activity against resistant Escherichia coli in an in vitro pharmacodynamic
More informationSumma Health System, Akron, Ohio and North-eastern Ohio Universities College of Medicine, Rootstown, Ohio, USA
REVIEW Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia T. M. File Jr Summa Health System, Akron, Ohio and North-eastern Ohio Universities College of Medicine, Rootstown,
More informationChemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance
Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance evolution of antimicrobial resistance Mechanism of bacterial genetic variability Point mutations may occur in a nucleotide base pair,
More informationMeasure Information Form
Release Notes: Measure Information Form Version 3.0b **NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE** Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form
More informationP< cells/µl mg/dl P<0.01 P<0.01
Technical Reports Judicious Use of s for Pediatric Infection Global Strategies to Prevent the Increase of Bacterial Resistance Kazunobu OUCHI Principle of antimicrobial therapy in children is to select
More informationTel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationJournal of Antimicrobial Chemotherapy Advance Access published August 26, 2006
Journal of Antimicrobial Chemotherapy Advance Access published August, Journal of Antimicrobial Chemotherapy doi:./jac/dkl Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae,
More informationCommunity-Acquired Pneumonia (CAP)
Community-Acquired Pneumonia (CAP) Infectious Diseases Advisory Board 14/01/2000 - Woluwé St Lambert Colloquium Longartsen - 11/02/2000 Dr Yvan Valcke Belgian guidelines on the initial diagnostic and therapeutic
More informationAUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin
Journal of Antimicrobial Chemotherapy (2002) 50, 533 539 DOI: 10.1093/jac/dkf177 AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin
More informationTreatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance
Journal of Antimicrobial Chemotherapy (2008) 61, 1162 1168 doi:10.1093/jac/dkn073 Advance Access publication 29 February 2008 Treatment costs associated with community-acquired pneumonia by community level
More informationAntibiotics in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Antibiotics in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease Sung Kyu Kim, M.D.Young Sam Kim, M.D. Department of Internal Medicine Yonsei University College of Medicine,
More informationPrinciples and Practice of Antimicrobial Susceptibility Testing. Microbiology Technical Workshop 25 th September 2013
Principles and Practice of Antimicrobial Susceptibility Testing Microbiology Technical Workshop 25 th September 2013 Scope History Why Perform Antimicrobial Susceptibility Testing? How to Perform an Antimicrobial
More informationStreptococcus pneumoniae Bacteremia: Duration of Previous Antibiotic Use and Association with Penicillin Resistance
MAJOR ARTICLE Streptococcus pneumoniae Bacteremia: Duration of Previous Antibiotic Use and Association with Penicillin Resistance Jörg J. Ruhe and Rodrigo Hasbun Department of Medicine, Infectious Diseases
More informationChristine E. Thorburn and David I. Edwards*
Journal of Antimicrobial Chemotherapy (2001) 48, 15 22 JAC The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence
More informationShould we test Clostridium difficile for antimicrobial resistance? by author
Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first
More informationmoxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering
moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering 05 November 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationSeasonality of Antibiotic#Resistant Streptococcus pneumoniae That Causes Acute Otitis Media: A Clue for an Antibiotic#Restriction Policy?
Seasonality of Antibiotic#Resistant Streptococcus pneumoniae That Causes Acute Otitis Media: A Clue for an Antibiotic#Restriction Policy? The Harvard community has made this article openly available. Please
More information11/10/2016. Skin and Soft Tissue Infections. Disclosures. Educational Need/Practice Gap. Objectives. Case #1
Disclosures Selecting Antimicrobials for Common Infections in Children FMR-Contemporary Pediatrics 11/2016 Sean McTigue, MD Assistant Professor of Pediatrics, Pediatric Infectious Diseases Medical Director
More informationCME/CE QUIZ CME/CE QUESTIONS. a) 20% b) 22% c) 34% d) 35% b) Susceptible and resistant strains of typical respiratory
CME/CE QUIZ CME/CE QUESTIONS Continuing Medical Education Accreditation This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for
More informationPrinciples in antimicrobial therapy: The ABCs
Principles in antimicrobial therapy: The ABCs Benjamin G. Co, MD, FPPS, FPSECP Professorial lecturer in Antimicrobial Therapy, Graduate School University of Santo Tomas Executive Director, Center for Drug
More informationWhy we perform susceptibility testing
22 nd June 2015 Why we perform susceptibility testing Robin A Howe Antimicrobial use in Primary Care Why do we perform AST? Clinical Clinical Prediction Prediction of of Efficacy Efficacy Why do we perform
More informationagainst Clinical Isolates of Gram-Positive Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,
More informationJAC Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model
Journal of Antimicrobial Chemotherapy (2000) 46, 981 985 JAC Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model Philippe Cottagnoud a *, Cynthia M. Gerber
More informationWhat Have We Learned from Pharmacokinetic and Pharmacodynamic Theories?
SUPPLEMENT ARTICLE PHARMACOLOGY What Have We Learned from Pharmacokinetic and Pharmacodynamic Theories? Jerome J. Schentag, Kristin K. Gilliland, and Joseph A. Paladino State University of New York at
More informationSeasonality of Antibiotic-Resistant Streptococcus pneumoniae That Causes Acute Otitis Media: A Clue for an Antibiotic-Restriction Policy?
MAJOR ARTICLE Seasonality of Antibiotic-Resistant Streptococcus pneumoniae That Causes Acute Otitis Media: A Clue for an Antibiotic-Restriction Policy? Ron Dagan, 1 Galia Barkai, 1 Noga Givon-Lavi, 1 Amir
More informationAntimicrobial Resistance Trends in the Province of British Columbia
655 West 12th Avenue Vancouver, BC V5Z 4R4 Tel 604.707.2443 Fax 604.707.2441 www.bccdc.ca Antimicrobial Resistance Trends in the Province of British Columbia 2013 Prepared by the Do Bugs Need Drugs? Program
More informationFluoroquinolones in 2007: the Angels, the Devils, and What Should the Clinician Do?
Fluoroquinolones in 2007: the Angels, the Devils, and What Should the Clinician Do? David C. Hooper, M.D. Division of Infectious Diseases Infection Control Unit Massachusetts General Hospital Harvard Medical
More informationContribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections
Contribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections Francois JEHL Laboratory of Clinical Microbiology University Hospital Strasbourg
More informationIn vitro Activity of Gemifloxacin Against Recent Clinical Isolates of Bacteria in Korea
J Korean Med Sci 2002; 17: 737-42 ISSN 1011-8934 Copyright The Korean Academy of Medical Sciences In vitro Activity of Gemifloxacin Against Recent Clinical Isolates of Bacteria in Korea Gemifloxacin is
More informationWhat is the problem? Latest data on antibiotic resistance
European Antibiotic Awareness Day 2009 What is the problem? Latest data on antibiotic resistance Zsuzsanna Jakab, ECDC Director Launch Seminar for EAAD Stockholm, 18 November 2009 Fluoroquinolone-resistant
More informationReceived 17 December 2003; accepted 22 December 2003
Journal of Antimicrobial Chemotherapy (2004) 53, 609 615 DOI: 10.1093/jac/dkh130 Advance Access publication 3 March 2004 In vitro post-antibiotic effect of fluoroquinolones, macrolides, β-lactams, tetracyclines,
More informationGARY WOODNUTT* AND VALERIE BERRY SmithKline Beecham Pharmaceuticals, Collegeville, Pennsylvania
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 1999, p. 29 34 Vol. 43, No. 1 0066-4804/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Two Pharmacodynamic Models for Assessing
More informationApproach to pediatric Antibiotics
Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus
More informationGuidelines for Empiric Antimicrobial Prescribing in Community-Acquired Pneumonia*
special reports Guidelines for Empiric Antimicrobial Prescribing in Community-Acquired Pneumonia* Thomas M. File, Jr, MD, FCCP; Javier Garau, MD; Francesco Blasi, MD, PhD; Christian Chidiac, MD; Keith
More informationANTIBIOTICS: TECHNOLOGIES AND GLOBAL MARKETS
ANTIBIOTICS: TECHNOLOGIES AND GLOBAL MARKETS PHM025D March 2016 Neha Maliwal Project Analyst ISBN: 1-62296-252-4 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationBarriers to Intravenous Penicillin Use for Treatment of Nonmeningitis
JCM Accepts, published online ahead of print on 7 July 2010 J. Clin. Microbiol. doi:10.1128/jcm.01012-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationPostgraduate Course ERS Glasgow 2004 Antibiotics and the lung: pharmacokinetics
Antibiotics and the lung: pharmacokinetics Educational aims To explain the importance of pulmonary deposition of antimicrobials. To show that drugs that penetrate well and remain at the pulmonary sites
More informationEUCAST Expert Rules for Staphylococcus spp IF resistant to isoxazolylpenicillins
EUAST Expert Rules for 2018 Organisms Agents tested Agents affected Rule aureus Oxacillin efoxitin (disk diffusion), detection of meca or mec gene or of PBP2a All β-lactams except those specifically licensed
More informationPrinciples of Antimicrobial Therapy
Principles of Antimicrobial Therapy Key Points Early and rapid diagnosis of infection and prompt initiation of appropriate antimicrobial therapy, if warranted, are fundamental to reducing the mortality
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationPopulation distributions of minimum inhibitory concentration increasing accuracy and utility
Journal of Applied Microbiology ISSN 364-572 ORIGINAL ARTICLE Population distributions of minimum inhibitory concentration increasing accuracy and utility R 2 -Scientific, Sharnbrook, Bedfordshire, UK
More informationPneumonia considerations Galia Rahav Infectious diseases unit Sheba medical center
Pneumonia considerations 2017 Galia Rahav Infectious diseases unit Sheba medical center Sir William Osler (1849 1919) "Father of modern medicine Pneumonia: The old man's friend The captain of the men of
More informationPinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu
Search for: Search Search Does levaquin cover anaerobes Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu Levofloxacin, sold under the trade names Levaquin among others, is an antibiotic.
More informationAlasdair P. MacGowan,* Chris A. Rogers, H. Alan Holt, and Karen E. Bowker
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2003, p. 1088 1095 Vol. 47, No. 3 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.3.1088 1095.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationWORKSHOP 6 Towards European consensus indications for major antibiotic classes: an exercise with the macrolides. Objectives
Objectives To establish the basic pharmacokinetic properties and safety profile of predefined macrolides. To make an inventory of the intrinsic susceptibilities of pathogenic organisms towards macrolides
More informationAdvanced Practice Education Associates. Antibiotics
Advanced Practice Education Associates Antibiotics Overview Difference between Gram Positive(+), Gram Negative(-) organisms Beta lactam ring, allergies Antimicrobial Spectra of Antibiotic Classes 78 Copyright
More informationDoxycycline for strep pneumonia
Doxycycline for strep pneumonia Antibiotic Levofloxacin (Levaquin) 750 mg, 500 mg for the treatment of respiratory, skin, and urinary tract infections, user reviews and ratings. 14-12-1995 John G. Bartlett,
More informationEmergence of Antibiotic Resistance in Upper and
...PRESENTATIONS... Emergence of Antibiotic Resistance in Upper and Lower Respiratory Tract Infections Michael R. Jacobs, MB, BCh, PhD Presentation Summary The increase in antibiotic resistance is of great
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More informationInitial Management of Infections in the Era of Enhanced Antimicrobial Resistance
Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance Robert C Welliver Sr, MD Hobbs-Recknagel Endowed Chair in Pediatrics Chief, Pediatric infectious Diseases Children s Hospital
More information